Trials that use: Covariate adjustment
5,848 results
- ObePso-SIndependent statistical analysis of Study to Explore the Effect of Secukinumab, Compared to Placebo, on Fat Tissue and Skin in Plaque Psoriasis Patients: primary endpoint results, effect estimate with confidence interval, sample-size…
- Obesity and Nonalcoholic Fatty Liver Disease: Complete Statistical AnalysisIndependent statistical analysis of Obesity and Nonalcoholic Fatty Liver Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00262964).
- Obesity, Sleep Apnea, and Insulin Resistance: Complete Statistical AnalysisIndependent statistical analysis of Obesity, Sleep Apnea, and Insulin Resistance: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02192684).
- Observation or Radiation Therapy in Treating Patients With Grade I, Grade II, or Grade III Meningioma: Complete Statistical AnalysisIndependent statistical analysis of Observation or Radiation Therapy in Treating Patients With Grade I, Grade II, or Grade III Meningioma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Observational Study of Deferiprone (Ferriprox®) in the Treatment of Superficial Siderosis: Complete Statistical AnalysisIndependent statistical analysis of Observational Study of Deferiprone (Ferriprox®) in the Treatment of Superficial Siderosis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Observational Study on Hypothyroidism in Young Children Following Iodine Contrast Exposure: Complete Statistical AnalysisIndependent statistical analysis of Observational Study on Hypothyroidism in Young Children Following Iodine Contrast Exposure: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- OCEANIndependent statistical analysis of Randomized Study of Obicetrapib in Combination With Ezetimibe: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04770389).
- Ocular Comfort and OCT Observation of Post Lens Clearance and Ocular Tissue Compression: Complete Statistical AnalysisIndependent statistical analysis of Ocular Comfort and OCT Observation of Post Lens Clearance and Ocular Tissue Compression: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Ocular Safety Of Patients Receiving Macugen For Neovascular Age Related Macular Degeneration: Complete Statistical AnalysisIndependent statistical analysis of Ocular Safety Of Patients Receiving Macugen For Neovascular Age Related Macular Degeneration: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- ODENIndependent statistical analysis of ODEN Trial: Option vs. Denali IVC Filters: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02201277).
- ODYSSEY FH IIIndependent statistical analysis of Study of Alirocumab (REGN727/SAR236553) in Patients With heFH (Heterozygous Familial Hypercholesterolemia) Who Are Not Adequately Controlled With Their LMT (Lipid-Modifying Therapy): primary endpoint results, effect estimate with confidence…
- ODYSSEY HoFHIndependent statistical analysis of Study in Participants With Homozygous Familial Hypercholesterolemia (HoFH): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03156621).
- Ofatumumab and Bendamustine Followed by Maintenance Ofatumumab for Rituximab Relapsed Indolent B-cell Non-Hodgkin’s Lymphoma (B-NHL): Complete Statistical AnalysisIndependent statistical analysis of Ofatumumab and Bendamustine Followed by Maintenance Ofatumumab for Rituximab Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (B-NHL): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Ofatumumab for Minimal Residual Disease (MRD) and Maintenance Therapy: Complete Statistical AnalysisIndependent statistical analysis of Ofatumumab for Minimal Residual Disease (MRD) and Maintenance Therapy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01258933).
- Ofatumumab With High Dose Methylprednisone Followed by Ofatumumab and Alemtuzumab in 17p CLL: Complete Statistical AnalysisIndependent statistical analysis of Ofatumumab With High Dose Methylprednisone Followed by Ofatumumab and Alemtuzumab in 17p CLL: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- OHTSIndependent statistical analysis of Ocular Hypertension Treatment Study (OHTS): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00000125).
- OIIndependent statistical analysis of Multicenter,Single-arm Study to Evaluate Efficacy, Safety, & Pharmacokinetics of Denosumab in Children w/ OI: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- OKQ2Independent statistical analysis of One Key Question: Pilot Study at NorthShore: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03947788).
- OLAIndependent statistical analysis of Oligonucleotide Ligation Assay (OLA) Resistance Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01898754).
- OLAPCOIndependent statistical analysis of OLAParib COmbinations: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02576444).
- OLIFIndependent statistical analysis of OptiMesh® for Lumbar Interbody Fusion Trial (OLIF): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00764491).
- Olmesartan Comparison to Losartan in Hypertensive Subjects: Complete Statistical AnalysisIndependent statistical analysis of Olmesartan Comparison to Losartan in Hypertensive Subjects: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00949884).
- Olmesartan/HCTZ 40/12.5 mg Combination Therapy Versus Olmesartan Medoxomil 40 mg Monotherapy in Essential Hypertension: Complete Statistical AnalysisIndependent statistical analysis of Olmesartan/HCTZ 40/12.5 mg Combination Therapy Versus Olmesartan Medoxomil 40 mg Monotherapy in Essential Hypertension: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- OLOLIndependent statistical analysis of Our Lifestyles Our Lives: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02965729).
- Olopatadine Eye Drops and Allergy Skin Testing: Complete Statistical AnalysisIndependent statistical analysis of Olopatadine Eye Drops and Allergy Skin Testing: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00775658).
- OlympiADIndependent statistical analysis of the OlympiAD phase 3 trial of olaparib monotherapy versus physician's choice chemotherapy in metastatic breast cancer patients with germline BRCA1/2 mutations.
- OlympiADIndependent statistical analysis of Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations.: primary endpoint results,…
- Omalizumab in Patients With Moderate to Severe Persistent Allergic Asthma Not Adequately Controlled Despite GINA (2009) Step 4 Therapy: Complete Statistical AnalysisIndependent statistical analysis of Omalizumab in Patients With Moderate to Severe Persistent Allergic Asthma Not Adequately Controlled Despite GINA (2009) Step 4 Therapy: primary endpoint results, effect estimate with confidence interval, sample-size…
- Omalizumab in the Treatment of Peanut Allergy: Complete Statistical AnalysisIndependent statistical analysis of Omalizumab in the Treatment of Peanut Allergy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00949078).
- Omentectomy and Metabolic Syndrome: Complete Statistical AnalysisIndependent statistical analysis of Omentectomy and Metabolic Syndrome: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00923260).
- OMS302-ILR-003Independent statistical analysis of Safety and Efficacy of OMS302 in Subjects Undergoing Intraocular Lens Replacement With Phacoemulsification: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- OMWaNAIndependent statistical analysis of Kangaroo Mother Care Before Stabilisation Amongst Low Birth Weight Neonates in Africa: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- ON TARGET DMIndependent statistical analysis of Comparison of Type 2 Diabetes Pharmacotherapy Regimens: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05073692).
- On-OffIndependent statistical analysis of On Versus Off Pump Myocardial Revascularization Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01290952).
- Once-Daily Asenapine for Schizophrenia: Complete Statistical AnalysisIndependent statistical analysis of Once-Daily Asenapine for Schizophrenia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01549041).
- onceMRKIndependent statistical analysis of Evaluation of the Safety and Efficacy of Reformulated Raltegravir (MK-0518) 1200 mg Once Daily in Combination With TRUVADA™ in Human Immunodeficiency Virus (HIV)-1 Infected, Treatment-Naive Participants (MK-0518-292): primary…
- Oncolo-GISTIndependent statistical analysis of Giving Information Systematically and Transparently in Lung and GI Cancer Phase 2: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Ondansetron and the QT Interval In Adult Emergency Department Patients: Complete Statistical AnalysisIndependent statistical analysis of Ondansetron and the QT Interval In Adult Emergency Department Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01759420).
- One Year Antibody Persistence After a Fourth Dose Boost or Two Catch-Up Doses of Novartis Meningococcal B Recombinant Vaccine Administered Starting From 12 Months of Age and Response to a Third Dose Boost or Two Catch-Up Doses Starting at 24 Months of Age: Complete Statistical AnalysisIndependent statistical analysis of One Year Antibody Persistence After a Fourth Dose Boost or Two Catch-Up Doses of Novartis Meningococcal B Recombinant Vaccine Administered Starting From 12 Months of Age and Response…
- One Year Study of Rifaximin Delayed Release (DR) in Crohn’s Disease: Complete Statistical AnalysisIndependent statistical analysis of One Year Study of Rifaximin Delayed Release (DR) in Crohn's Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- One-Day Acceptance and Commitment Training Intervention in Primary Care Patients: Complete Statistical AnalysisIndependent statistical analysis of One-Day Acceptance and Commitment Training Intervention in Primary Care Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01879800).
- One-Day Dispensing Clinical Evaluation of SofLens Daily Disposable Lenses Compared to a Marketed 1 Day Contact Lens: Complete Statistical AnalysisIndependent statistical analysis of One-Day Dispensing Clinical Evaluation of SofLens Daily Disposable Lenses Compared to a Marketed 1 Day Contact Lens: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- One-Day Life Skills Workshop for Veterans With TBI, Pain and Psychopathology: Complete Statistical AnalysisIndependent statistical analysis of One-Day Life Skills Workshop for Veterans With TBI, Pain and Psychopathology: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- One-Year Trial of Oral Ziprasidone in Bipolar Patients With Metabolic Syndrome: Complete Statistical AnalysisIndependent statistical analysis of One-Year Trial of Oral Ziprasidone in Bipolar Patients With Metabolic Syndrome: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Online Caregiver Psychoeducation and Support for Alzheimer’s: Complete Statistical AnalysisIndependent statistical analysis of Online Caregiver Psychoeducation and Support for Alzheimer's: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00416078).
- Online MBCT Program for University Students: Complete Statistical AnalysisIndependent statistical analysis of Online MBCT Program for University Students: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05804877).
- Online Survey in Studying Smoking Attitudes and Behaviors Among Current Smokers: Complete Statistical AnalysisIndependent statistical analysis of Online Survey in Studying Smoking Attitudes and Behaviors Among Current Smokers: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- ONPEDIndependent statistical analysis of Oral Naltrexone In Pediatric Eating Disorders: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05073679).
- onset 9Independent statistical analysis of onset 9, a randomized phase 3 trial comparing faster-acting insulin aspart with NovoRapid in people with type 2 diabetes, including its non-inferiority analysis of HbA1c change.
- onset 9Independent statistical analysis of Research Study Comparing a New Medicine "Fast-acting Insulin Aspart" to Another Already Available Medicine "NovoRapid"/"NovoLog" in People With Type 2 Diabetes: primary endpoint results, effect estimate with confidence…